LG Group has recently surpassed a cumulative investment amount of USD 50 million (approximately KRW 6.95 billion) in the bio sector by acquiring shares in a U.S. cancer treatment developer.

According to LG Group on the 3rd, its corporate venture capital (CVC) arm, LG Technology Ventures, has participated as a Series B (investment stage for growth after business feasibility verification) investor in 'Strand Therapeutics,' a messenger RNA (mRNA) therapeutics developer based in Cambridge, Massachusetts. The investment amount was not disclosed.

Strand Therapeutics was founded in 2017 by bioengineering graduates from the Massachusetts Institute of Technology (MIT). The company is developing treatments for cancer, autoimmune diseases, and rare diseases through technology that programs cells in the body to produce the appropriate amount of antigens at the right time.

The cumulative investment amount in the bio sector by LG Technology Ventures is estimated to have exceeded USD 50 million with this investment. By the end of last year, LG Group's total investment in the bio sector was USD 35 million, and it is reported that an additional USD 15 million has been invested this year. LG Group previously invested in 'Adipo Therapeutics,' a rare obesity treatment developer, and 'Aetion,' a healthcare data analysis platform company. An LG Group representative stated, "We are expanding strategic investments in the ABC (AI, Bio, Cleantech) fields, which have high future growth potential."

Popular News